Efficacy and tolerance of a novel topical TRPV ‐1 channel antagonist in dogs with allergic pododermatitis
Veterinary Dermatology · 2023
DOI: 10.1111/vde.13185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Dermatology, 2023. Verfasst von Xavier Serra Fabregat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clínica Veterinària Més Que Gossos, Santa Coloma de Gramenet, Barcelona, Spain. Hauptthemen laut MEDLINE: Coinfection, Hypersensitivity, Dermatitis, Atopic, Dog Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vetilea SL.
Abstract (Originalsprache)
Background
Pruritus due to allergic skin disease is one of the most common reasons for dermatological consultations in the veterinary clinic. Treatment is usually multimodal and requires continuous monitoring and reassessment. New therapies are needed to broaden the therapeutic arsenal. Hypothesis/Objectives The aim of this study was to evaluate the efficacy of a novel transient receptor potential vanilloid 1 (TRPV1) channel antagonist for allergic pododermatitis in dogs. Animals Twenty‐four client‐owned dogs with allergic pododermatitis. Materials and Methods The study was an open, prospective, multi‐centre clinical trial with client‐owned dogs. All dogs were treated twice daily with a spray containing hydroxymethoxyiodobenzyl glycolamide pelargonate for 28 days. Clinical assessments included pruritus Visual Analog Scale (PVAS), pedal skin lesion score, evaluation of quality of life (QoL), presence of secondary infections and a four‐point subjective efficacy assessment by the veterinarian and the dog owner.
Results
There was more than 50% improvement in all scores by the conclusion of the study. Secondary infections were reduced ( p < 0.001). Both the veterinarians and dog owners evaluated the efficacy of the product positively. The product was well‐tolerated. Conclusions and Clinical Relevance This study demonstrated the tolerability and efficacy of a TRPV1 antagonist on pruritic pododermatitis in 24 dogs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clínica Veterinària Més Que Gossos, Santa Coloma de Gramenet, Barcelona, Spain.
- Evidensia Hospital Veterinario Mediterráneo, Madrid, Spain.
- Clínica Veterinaria Centauro, Alcorcón, Spain.
- Hospital Veterinario Anicura Abros, Ourense, Spain.
- Universitat Autònoma de Barcelona, Bellaterra, Spain.
- Vetilea SL, Esplugues de Llobregat, Barcelona, Spain.
ORCID-Profile: Elsa Genové Corominas
Förderung
- Vetilea SL
Zitieren
APA
Serra Fabregat, X., de Pablo, M. Á., Hernán-Pérez, C., Diéguez, E., Valero Coppin, O., & Genové Corominas, E. (2023). Efficacy and tolerance of a novel topical TRPV ‐1 channel antagonist in dogs with allergic pododermatitis. Veterinary Dermatology. https://doi.org/10.1111/vde.13185
Vancouver
Serra Fabregat X, de Pablo MÁ, Hernán-Pérez C, Diéguez E, Valero Coppin O, Genové Corominas E. Efficacy and tolerance of a novel topical TRPV ‐1 channel antagonist in dogs with allergic pododermatitis. Veterinary Dermatology. 2023. doi:10.1111/vde.13185
BibTeX
@article{SerraFabregat2023,
author = {Serra Fabregat, Xavier and de Pablo, Miguel Ángel and Hernán-Pérez, Conchita and Diéguez, Elena and Valero Coppin, Oliver and Genové Corominas, Elsa},
title = {Efficacy and tolerance of a novel topical TRPV ‐1 channel antagonist in dogs with allergic pododermatitis},
journal = {Veterinary Dermatology},
year = {2023},
doi = {10.1111/vde.13185}
}
EUVIMED